1887

Abstract

We established a new ‘transmission kinetic assay (TKA)’ to quantify the human cytomegalovirus (HCMV) transmission between cells and to phenotypically characterize HCMV strains based on their mode of transmission by flow cytometric analysis. On one hand we used the genetically modified HCMV strain TB40/E-delUL16-GFP, and on the other hand, clinical isolates. When twofold diluted infecting cells were seeded to a constant number of uninfected cells, the transmission of virus on each day (day 0–5) followed a strictly linear pattern, which was characterized by a linear equation. The slope of this linear equation represents ‘the number of newly infected cells per infecting cell’. To standardize the TKA, the slopes of the different days were plotted against the corresponding days. This resulted in a new linear equation with a new slope value, which characterizes the transmission kinetics. To differentiate cell-associated and cell-free modes of transmission, we introduced HCMV neutralizing antibodies into the system. The slope was 0.9 (±0.5) when the virus exhibited only cell-associated transmission and was 4.1 (±0.7) when the virus exhibited both modes of transmission. TKA was then applied to different clinical isolates and they were phenotypically characterized based on their modes of transmission. Apart from the quantitative analysis of HCMV transmission and the phenotypical characterization of clinical isolates, the TKA was applied to quantify the inhibition of clinical isolates transmission by immune cells and to study the effect of cytokine (IL-2) on immune cells inhibiting HCMV transmission.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.000543
2016-09-01
2020-04-09
Loading full text...

Full text loading...

/deliver/fulltext/jgv/97/9/2376.html?itemId=/content/journal/jgv/10.1099/jgv.0.000543&mimeType=html&fmt=ahah

References

  1. Adler B., Scrivano L., Ruzcics Z., Rupp B., Sinzger C., Koszinowski U.. 2006; Role of human cytomegalovirus UL131A in cell type-specific virus entry and release. J Gen Virol87:2451–2460 [CrossRef][PubMed]
    [Google Scholar]
  2. Cannon M. J., Schmid D. S., Hyde T. B.. 2010; Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol20:202–213 [CrossRef][PubMed]
    [Google Scholar]
  3. Cheeran M. C., Lokensgard J. R., Scleiss M. R.. 2009; Neuropathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for intervention. Clin Microbiol Rev22:99–126 [CrossRef][PubMed]
    [Google Scholar]
  4. Chevillotte M., Schubert A., Mertens T., von Einem J.. 2009; Fluorescence-based assay for phenotypic characterization of human cytomegalovirus polymerase mutations regarding drug susceptibility and viral replicative fitness. Antimicrob Agents Chemother53:3752–3761 [CrossRef][PubMed]
    [Google Scholar]
  5. Cui X., Lee R., Adler S. P., McVoy M. A.. 2013; Antibody inhibition of human cytomegalovirus spread in epithelial cell cultures. J Virol Methods192:44–50 [CrossRef][PubMed]
    [Google Scholar]
  6. Dargan D. J., Douglas E., Cunningham C., Jamieson F., Stanton R. J., Baluchova K., McSharry B. P., Tomasec P., Emery V. C. et al. 2010; Sequential mutations associated with adaptation of human cytomegalovirus to growth in cell culture. J Gen Virol91:1535–1546 [CrossRef][PubMed]
    [Google Scholar]
  7. De Sanctis J. B., Blanca I., Bianco N. E.. 1997; Secretion of cytokines by natural killer cells primed with interleukin-2 and stimulated with different lipoproteins. J Immunol90:526–533 [CrossRef][PubMed]
    [Google Scholar]
  8. Digel M., Sampaio K. L., Jahn G., Sinzger C.. 2006; Evidence for direct transfer of cytoplasmic material from infected to uninfected cells during cell-associated spread of human cytomegalovirus. J Clin Virol37:10–20 [CrossRef][PubMed]
    [Google Scholar]
  9. Djaoud Z., David G., Bressollette C., Willem C., Rettman P., Gagne K., Legrand N., Mehlal S., Cesbron A. et al. 2013; Amplified NKG2C+ NK cells in cytomegalovirus (CMV) infection preferentially express killer cell Ig-like receptor 2DL: functional impact in controlling CMV-infected dendritic cells. J Immunol191:2708–2716 [CrossRef][PubMed]
    [Google Scholar]
  10. Emery V. C.. 1999; Investigation of CMV disease in immunocompromised patients. J Clin Pathol54:84–88 [CrossRef]
    [Google Scholar]
  11. Fouts A. E., Chan P., Stephan J. P., Vandlen R., Feierbach B.. 2012; Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (Anti-CMV) neutralizing antibody response in CMV hyperimmune globulin. J Virol86:7444–7447 [CrossRef][PubMed]
    [Google Scholar]
  12. Gerna G., Zavattoni M., Percivalle E., Zella D., Torsellini M., Revello M. G.. 1996; Diagnosis of human cytomegalovirus infections in the immunocompromised host. Clin Diagn Virol5:181–186 [CrossRef][PubMed]
    [Google Scholar]
  13. Gerna G., Sarasini A., Patrone M., Percivalle E., Fiorina L., Campanini G., Gallina A., Baldanti F., Revello M. G.. 2008; Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection. J Gen Virol89:853–865 [CrossRef][PubMed]
    [Google Scholar]
  14. Griffiths P. D.. 2012; Burden of disease associated with human cytomegalovirus and prospects for elimination by universal immunisation. Lancet Infect Dis12:790–798 [CrossRef][PubMed]
    [Google Scholar]
  15. Jackson S. E., Mason G. M., Okecha G., Sissons J. G., Wills M. R.. 2014; Diverse specificities, phenotypes, and antiviral activities of cytomegalovirus-specific CD8+ T cells. J Virol88:10894–10908 [CrossRef][PubMed]
    [Google Scholar]
  16. Jacob C. L., Lamorte L., Sepulveda E., Lorenz I. C., Gauthier A., Franti M.. 2013; Neutralizing antibodies are unable to inhibit direct viral cell-to-cell spread of human cytomegalovirus. Virology444:140–147 [CrossRef][PubMed]
    [Google Scholar]
  17. Jost S., Alfred M.. 2013; Control of human viral infections by natural killer cells. Annu Rev Immunol31:163–194 [CrossRef][PubMed]
    [Google Scholar]
  18. Kahl M., Siegel-Axel D., Stenglein S., Jahn G., Sinzger C.. 2000; Efficient lytic infection of human arterial endothelial cells by human cytomegalovirus strains. J Virol74:7628–7635 [CrossRef][PubMed]
    [Google Scholar]
  19. Landry M. L., Stanat S., Biron K., Brambilla D., Britt W., Jokela J., Chou S., Drew W. L., Erice A. et al. 2000; A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates. Antimicrob Agents Chemother 44:688–692 [CrossRef][PubMed]
    [Google Scholar]
  20. Li H., Mao G., Carlson J., Leng S. X.. 2015; A novel flow cytometry-based tool for determining the efficiency of human cytomegalovirus infection in THP-1 derived macrophages. J Virol Methods221:127–130 [CrossRef][PubMed]
    [Google Scholar]
  21. Mocarski E.. 1996; Cytomegalovirus and their replication. In Fields Virology , pp.2447–2492 Edited by Fields B. N., Knipe D. M., Howley P. M.. New York: Lippincott-Raven;
    [Google Scholar]
  22. Osborn J. E.. 1982; Cytomegalovirus and other herpesviruses. In The Mouse in Biomedical Research. II. Diseases , pp.267–292 Edited by Foster H. L., Small J. D., Fox J. G.. New York: Academic;
    [Google Scholar]
  23. Prichard M. N., Penfold M. E., Duke G. M., Spaete R. R., Kemble G. W.. 2001; A review of genetic differences between limited and extensively passaged human cytomegalovirus strains. Rev Med Virol11:191–200 [CrossRef][PubMed]
    [Google Scholar]
  24. Sattentau Q.. 2008; Avoiding the void: cell-to-cell spread of human viruses. Nat Rev Microbiol6:815–826 [CrossRef][PubMed]
    [Google Scholar]
  25. Sinclair J., Sissons P.. 2006; Latency and reactivation of human cytomegalovirus. J Gen Virol87:1763–1779 [CrossRef][PubMed]
    [Google Scholar]
  26. Sinzger C., Knapp J., Plachter B., Schmidt K., Jahn G.. 1997; Quantification of replication of clinical cytomegalovirus isolates in cultured endothelial cells and fibroblasts by a focus expansion assay. J Virol Methods63:103–112 [CrossRef][PubMed]
    [Google Scholar]
  27. Sinzger C., Schmidt K., Knapp J., Kahl M., Beck R., Waldman J., Hebart H., Einsele H., Jahn G.. 1999; Modification of human cytomegalovirus tropism through propagation in vitro is associated with changes in the viral genome. J Gen Virol80:2867–2877 [CrossRef][PubMed]
    [Google Scholar]
  28. Sinzger C., Mangin M., Weinstock C., Topp M. S., Hebart H., Einsele H., Jahn G.. 2007; Effect of serum and CTL on focal growth of human cytomegalovirus. J Clin Virol38:112–119 [CrossRef][PubMed]
    [Google Scholar]
  29. Stanton R. J., Baluchova K., Dargan D. J., Cunningham C., Sheehy O., Serafian S., McSharry B. P., Neale M. L., Davies J. A. et al. 2010; Reconstruction of the complete human cytomegalovirus genome in a BAC reveals RL13 to be a point inhibitor of replication. J Clin Invest37:3191–3208[CrossRef]
    [Google Scholar]
  30. Tabi Z., Moutaftsi M., Borysiewicz L. K.. 2001; Human cytomegalovirus pp65- and immediate early 1 antigen-specific HLA class I-restricted cytotoxic T cell responses induced by cross-presentation of viral antigens. J Immunol166:5695–5703 [CrossRef][PubMed]
    [Google Scholar]
  31. Wills M. R., Poole E., Lau B., Krishna B., Sinclair J. H.. 2015; The immunology of human cytomegalovirus latency: could latent infection be cleared by novel immunotherapeutic strategies?. Cell Mol Immunol12:128–138 [CrossRef][PubMed]
    [Google Scholar]
  32. Wu Z., Frascaroli G., Mertens T.. 2013; Assessment of natural killer cell responses to human cytomegalovirus-infected macrophages. Methods Mol Biol1064:289–298 [CrossRef][PubMed]
    [Google Scholar]
  33. Wu Z., Sinzger C., Reichel J. J., Just M., Mertens T.. 2015; Natural killer cells can inhibit the transmission of human cytomegalovirus in cell culture by using mechanisms from innate and adaptive immune responses. J Virol89:2906–2917 [CrossRef][PubMed]
    [Google Scholar]
  34. Wu Z., Frascaroli G., Bayer C., Schmal T., Mertens T.. 2015; Interleukin-2 from adaptive T Cells enhances natural killer cell activity against human cytomegalovirus-infected macrophages. J Virol89:6435–6441 [CrossRef]
    [Google Scholar]
  35. Yamane Y., Furukawa T., Plotkin S. A.. 1983; Supernatant virus release as a differentiating marker between low passage and vaccine strains of human cytomegalovirus. Vaccine1:23–25 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.000543
Loading
/content/journal/jgv/10.1099/jgv.0.000543
Loading

Data & Media loading...

Supplements

Supplementary File 1

PDF

Most cited this month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error